Yahoo
NasdaqCM - Nasdaq Real Time Price USD

INmune Bio Inc. (INMB)

2.4300 +0.0700 (+2.97%)
At close: August 25 at 4:00:01 PM EDT
2.4000 -0.0300 (-1.23%)
Pre-Market: 8:06:58 AM EDT
Chart Range Bar
Loading chart for INMB
  • Previous Close 2.3600
  • Open 2.4000
  • Bid 1.7600 x 200
  • Ask 3.0000 x 200
  • Day's Range 2.3500 - 2.4400
  • 52 Week Range 1.0900 - 2.4800
  • Volume 263,845
  • Avg. Volume 724,771
  • Market Cap (intraday) 67.442M
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6200
  • Earnings Date (est.) Oct 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.00

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

www.inmunebio.com

21

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INMB
55.77%
S&P 500 (^GSPC)
12.15%

1-Year Return

INMB
8.48%
S&P 500 (^GSPC)
19.23%

3-Year Return

INMB
69.28%
S&P 500 (^GSPC)
74.26%

5-Year Return

INMB
87.06%
S&P 500 (^GSPC)
70.75%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -1.27M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

4.00
7.00 Average
2.4300 Current
9.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/11/2026
Analyst LUCID CAPITAL MARKETS
Rating Action Upgrade
Rating Buy
Price Action Raises
Price Target 2 -> 9

Statistics

View More

Valuation Measures

Annual
As of 8/25/2026
  • Market Cap

    67.44M

  • Enterprise Value

    50.44M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    708.07

  • Price/Book (mrq)

    2.89

  • Enterprise Value/Revenue

    286.00

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -39.12%

  • Return on Equity (ttm)

    -74.82%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.42M

  • Diluted EPS (ttm)

    -0.6200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.41M

  • Total Debt/Equity (mrq)

    6.90%

  • Levered Free Cash Flow (ttm)

    -10.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.4300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: